Table 3.
Risks of Primary Malignancy Endpoint Location by Treatment Arm
| Organ Location | Simvastatin Monotherapy (n = 8,855) |
Simvastatin/Ezetimibe (n = 8,853) |
HR (95% CI) | p Value | ||
|---|---|---|---|---|---|---|
| n | Kaplan-Meier Event Rate at 7 Years (%) | n | Kaplan-Meier Event Rate at 7 Years (%) | |||
| Lung (bronchus) | 128 | 1.92 | 119 | 1.64 | 0.93 (0.73–1.20) | 0.59 |
| Prostate (men only) | 108/6,727 | 2.07 | 116/6,687 | 2.07 | 1.06 (0.82-1.38) | 0.64 |
| Bladder | 69 | 1.07 | 60 | 0.87 | 0.87 (0.62–1.23) | 0.44 |
| Colon | 48 | 0.67 | 60 | 0.81 | 1.25 (0.86–1.83) | 0.24 |
| Melanoma | 34 | 0.52 | 35 | 0.52 | 1.03 (0.64–1.65) | 0.90 |
| Breast | 28 | 0.43 | 38 | 0.54 | 1.36 (0.83–2.21) | 0.22 |
| In women | 27/2,128 | 1.83 | 38/2,166 | 2.33 | 1.41 (0.86–2.31) | 0.17 |
| In men | 1/6,727 | 0.02 | 0/6,687 | 0.00 | NA | NA |
| Kidney or ureter | 34 | 0.51 | 31 | 0.38 | 0.91 (0.56–1.49) | 0.72 |
| Lymphoma | 27 | 0.35 | 31 | 0.43 | 1.15 (0.69–1.93) | 0.60 |
| Pancreas | 30 | 0.43 | 20 | 0.34 | 0.67 (0.38–1.17) | 0.16 |
| Leukemia | 18 | 0.24 | 21 | 0.28 | 1.17 (0.62–2.19) | 0.63 |
| Head or neck | 18 | 0.25 | 17 | 0.24 | 0.95 (0.49–1.84) | 0.88 |
| Stomach | 12 | 0.17 | 15 | 0.24 | 1.25 (0.59–2.68) | 0.56 |
| Nervous system | 4 | 0.04 | 11 | 0.19 | 2.75 (0.88–8.63) | 0.08 |
| Ovarian or fallopian tube | 2/2,128 | 0.11 | 3/2,166 | 0.19 | NA | NA |
Malignancy locations are shown in order of frequency.
NA = not available; other abbreviations as in Table 2.